Abstract | BACKGROUND: AIM: METHODS: This multi-center, double-blind, randomized trial enrolled patients with endoscopically documented reflux esophagitis. Patients were assigned to receive either 20 mg S- pantoprazole or 40 mg pantoprazole once daily for 4 weeks. Endoscopy and symptoms were assessed after 4 weeks of treatment. In patients whose reflux esophagitis was not resolved at 4 weeks, treatment was extended to 8 weeks and symptoms were reassessed. Heartburn, chest pain, acid regurgitation, globus, and overall symptoms were rated. The primary efficacy endpoint was healing of esophagitis, and secondary endpoints were symptomatic and endoscopic improvement. RESULTS: CONCLUSION:
|
Authors | Yu Kyung Cho, Myung-Gyu Choi, Young-Tae Bak, Poong-Lyul Rhee, Sang Gyun Kim, Hoon-Yong Jung, Sang Young Seol |
Journal | Digestive diseases and sciences
(Dig Dis Sci)
Vol. 57
Issue 12
Pg. 3189-94
(Dec 2012)
ISSN: 1573-2568 [Electronic] United States |
PMID | 22772870
(Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- 2-Pyridinylmethylsulfinylbenzimidazoles
- Proton Pump Inhibitors
- Pantoprazole
|
Topics |
- 2-Pyridinylmethylsulfinylbenzimidazoles
(administration & dosage, chemistry, therapeutic use)
- Adult
- Dose-Response Relationship, Drug
- Double-Blind Method
- Esophagitis, Peptic
(drug therapy)
- Female
- Humans
- Male
- Middle Aged
- Pantoprazole
- Proton Pump Inhibitors
(administration & dosage, chemistry, therapeutic use)
|